Cryo-EM structure in situ reveals a molecular switch that safeguards virus against genome loss

  1. Oliver W Bayfield  Is a corresponding author
  2. Alasdair C Steven
  3. Alfred A Antson  Is a corresponding author
  1. University of York, United Kingdom
  2. NIAMS-NIH, United States

Abstract

The portal protein is a key component of many double-stranded DNA viruses, governing capsid assembly and genome packaging. Twelve subunits of the portal protein define a tunnel, through which DNA is translocated into the capsid. It is unknown how the portal protein functions as a gatekeeper, preventing DNA slippage, whilst allowing its passage into the capsid, and how these processes are controlled. A cryo-EM structure of the portal protein of thermostable virus P23-45, determined in situ in its procapsid-bound state, indicates a mechanism that naturally safeguards the virus against genome loss. This occurs via an inversion of the conformation of the loops that define the constriction in the central tunnel, accompanied by a hydrophilic–hydrophobic switch. The structure also shows how translocation of DNA into the capsid could be modulated by a changing mode of protein–protein interactions between portal and capsid, across a symmetry-mismatched interface.

Data availability

Cryo-EM reconstruction (EMD-4567) and atomic coordinates (PDB 6QJT) have been deposited with the wwPDB (www.wwpdb.org).

The following data sets were generated

Article and author information

Author details

  1. Oliver W Bayfield

    Chemistry, University of York, York, United Kingdom
    For correspondence
    oliver.bayfield@york.ac.uk
    Competing interests
    The authors declare that no competing interests exist.
  2. Alasdair C Steven

    Laboratory of Structural Biology, NIAMS-NIH, Bethesda, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. Alfred A Antson

    Chemistry, University of York, York, United Kingdom
    For correspondence
    fred.antson@york.ac.uk
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4533-3816

Funding

Wellcome (103460)

  • Oliver W Bayfield

Wellcome (206377)

  • Alfred A Antson

National Institute of Arthritis and Musculoskeletal and Skin Diseases (Intramural Research Program)

  • Alasdair C Steven

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

Metrics

  • 2,173
    views
  • 294
    downloads
  • 23
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Oliver W Bayfield
  2. Alasdair C Steven
  3. Alfred A Antson
(2020)
Cryo-EM structure in situ reveals a molecular switch that safeguards virus against genome loss
eLife 9:e55517.
https://doi.org/10.7554/eLife.55517

Share this article

https://doi.org/10.7554/eLife.55517

Further reading

    1. Computational and Systems Biology
    2. Structural Biology and Molecular Biophysics
    Bin Zheng, Meimei Duan ... Peng Zheng
    Research Article

    Viral adhesion to host cells is a critical step in infection for many viruses, including monkeypox virus (MPXV). In MPXV, the H3 protein mediates viral adhesion through its interaction with heparan sulfate (HS), yet the structural details of this interaction have remained elusive. Using AI-based structural prediction tools and molecular dynamics (MD) simulations, we identified a novel, positively charged α-helical domain in H3 that is essential for HS binding. This conserved domain, found across orthopoxviruses, was experimentally validated and shown to be critical for viral adhesion, making it an ideal target for antiviral drug development. Targeting this domain, we designed a protein inhibitor, which disrupted the H3-HS interaction, inhibited viral infection in vitro and viral replication in vivo, offering a promising antiviral candidate. Our findings reveal a novel therapeutic target of MPXV, demonstrating the potential of combination of AI-driven methods and MD simulations to accelerate antiviral drug discovery.

    1. Chromosomes and Gene Expression
    2. Structural Biology and Molecular Biophysics
    Liza Dahal, Thomas GW Graham ... Xavier Darzacq
    Research Article

    Type II nuclear receptors (T2NRs) require heterodimerization with a common partner, the retinoid X receptor (RXR), to bind cognate DNA recognition sites in chromatin. Based on previous biochemical and overexpression studies, binding of T2NRs to chromatin is proposed to be regulated by competition for a limiting pool of the core RXR subunit. However, this mechanism has not yet been tested for endogenous proteins in live cells. Using single-molecule tracking (SMT) and proximity-assisted photoactivation (PAPA), we monitored interactions between endogenously tagged RXR and retinoic acid receptor (RAR) in live cells. Unexpectedly, we find that higher expression of RAR, but not RXR, increases heterodimerization and chromatin binding in U2OS cells. This surprising finding indicates the limiting factor is not RXR but likely its cadre of obligate dimer binding partners. SMT and PAPA thus provide a direct way to probe which components are functionally limiting within a complex TF interaction network providing new insights into mechanisms of gene regulation in vivo with implications for drug development targeting nuclear receptors.